

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-178) FARICIMAB

PRONUNCIATION far ik' i mab

THERAPEUTIC CLAIM Opthamology indications in patients susceptible to blocking of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2)

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human angiopoietin 2) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer with immunoglobulin G1, anti-(human vascular endothelial growth factor A) (human-*Mus musculus* monoclonal heavy chain), disulfide with human-*Mus musculus* monoclonal light chain
2. Immunoglobulin G1-kappa/lambda with domain crossover, anti-*[Homo sapiens*-Vascular endothelial growth factor A (VEGF-A, Vascular permeability factor, VPF)] and anti-*[Homo sapiens*-Angiopoietin-2 (ANG-2)], humanized and *Homo sapiens* monoclonal antibody, bispecific; γ 1 heavy chain anti-VEGF-A (1-453) [humanized VH (*Homo sapiens* IGHV3-30*02 (76%) – (IGHD)-IGHJ4*01 (93%)) [8.9.16] (1-123) -*Homo sapiens* IGHG1*01 {CH2[L⁴>A(240), L⁵>A(241), I²³>A(259), H⁸⁰>A(316), P⁹⁹>G(335)], CH3[S¹⁴>C(360), T²⁶>W(372), H⁹⁵>A(441)]} (124-453)], (226-214')-disulfide with κ light chain anti-VEGF-A (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (87%) –IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; γ 1- κ heavy chain anti-ANG-2 (1"-463") [*Homo sapiens* VH (IGHV1-2*02–(IGHD)-IGHJ3*02) [8.8.22] (1"-129") -*Homo sapiens* IGKC*01 {R¹>A(130"),T²>S(131")} (130"-236") -*Homo sapiens* IGHG1*01 {del-CH1, Hinge-(6-15)>(237"-246"), CH2[L⁴>A(250"), L⁵>A(251"), I²³>A(269"), H⁸⁰>A(326"), P⁹⁹>G(345")], CH3[Y⁹>C(365"), T²⁶>S(382"), L²⁸>A(384"), Y⁶⁷>V(423"), H⁹⁵>A(451")}] (237"-463") (236"-213''')-disulfide with λ - γ -light chain anti-ANG-2 (1'''-213''') [*Homo sapiens* V-LAMBDA (IGLV3-21*02–IGLJ3*02)[6.3.11] (1'''-110''') -*Homo sapiens* IGHG1*01{CH1-Hinge-(1-5)} (111'''-213''')]; dimer (232-242"-235-245":360-365")-trisdisulfide

STRUCTURAL FORMULA

Heavy chain anti-VEGFA

EVQLVESGGG	LVQPGGSLRL	SCAASGYDFT	HYGMNWVRQA	PGKGLEWVWG	50
INTYTGEPY	AADFRRRTF	SLDTSKSTAY	LQMNSLRAED	TAVYYCAKYP	100
YYYGTSHWYF	DVWGQGLT	VSSASTKGPS	VFPLAPSSKS	TSGGTAALGC	150
LVKDYFPEPV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200
TQTYICNVNH	KPSNTKVDKK	VEPKSCDKTH	TCPPCPAPEA	AGGPSVFLFP	250
PKPKDTLMAS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV	HNAKTKPREE	300
QYNSTYRVVS	VLTVLAQDWL	NGKEYKCKVS	NKALGAPIEK	TISKAKGQPR	350
EPQVYTLPPC	RDELTKNQVS	LWCLVKGFYP	SDIAVEWESN	GQPENNYKTT	400
PPVLDSDGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN	AYTQKSLSLS	450
PGK					453

Light chain anti-VEGFA

DIQLTQSPSS	LSASVGDRVT	ITCSASQDIS	NYLNWYQQKP	GKAPKVLIIYF	50'
TSSLHSGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YSTVPWTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Heavy chain anti-ANGPT2

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	GYMHWVRQA	PGQGLEWMGW	50"
INPNSGGTNY	AQKFQGRVTM	TRDTSISTAY	MELSLRSD	TAVYYCARSP	100"
NPYYDSSGY	YYPGAFDIWG	QGTMTVSSA	SVAAPSVFIF	PPSDEQLKSG	150"
TASVVCLLNN	FYPREAKVQW	KVDNALQSGN	SQESVTEQDS	KDSTYLSLST	200"
LTLISKADYEK	HKVYACEVTH	QGLSSPVTKS	FNRGECDKTH	TCPPCPAPEA	250"
AGGPSVFLFP	PKPKDTLMAS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV	300"
HNAKTKPREE	QYNSTYRVVS	VLTVLAQDWL	NGKEYKCKVS	NKALGAPIEK	350"
TISKAKGQPR	EPQVCTLPPS	RDELTKNQVS	LSCAVKGFYP	SDIAVEWESN	400"
GQPENNYKTT	PPVLDSDGSF	FLVSKLTVDK	SRWQQGNVFS	CSVMHEALHN	450"
AYTQKSLSL	PGK				463"

Light chain anti-ANGPT2

SYVLTQPPSV	SVAPGQTARI	TCGGNNIGSK	SVHWYQQKPG	QAPVLVVYDD	50"
SDRPSGIPER	FSGSNSGNTA	TLTISRVEAG	DEADYVCQVW	DSSSDHWVFG	100"
GGTKLTVLSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	DYFPEPVTVS	150"
WNSGALTSVG	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	YICNVNHPKS	200"
NTKVDKKEP	KSC				213"

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22"-87"	22-96	22"-96"	23'-88'	134'-194'	137"-193"
150-206	156"-216"	213"-236'	214'-226	232-242"	235-245"
267-327	277"-337"	360-365"	373-431	383"-441"	

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-303 Asn-313"

MOLECULAR FORMULA C₆₅₀₆H₉₉₆₈N₁₇₂₄O₁₀₂₆S₄₅ (non-glycosylated)

MOLECULAR WEIGHT 146.43 kDa (non-glycosylated)

TRADEMARK None as yet

SPONSOR Genentech/Roche

CODE DESIGNATIONS RO6867461, RG7716

CAS REGISTRY NUMBER 1607793-29-2

UNII QC4F7FKK7I

WHO NUMBER 10563

gbk